Financial Performance - For the six months ended June 30, 2024, the Group's revenue amounted to HK$22.0 million, a decrease of HK$1.3 million or 5.6% from HK$23.3 million in the corresponding period last year[7]. - The Group's gross profit was HK$6.8 million, representing an increase of HK$1.9 million or 38.8% compared to HK$4.9 million for the same period last year, with a gross profit margin increase of 9.7 percentage points to 30.8%[7]. - The overall loss attributable to owners of the Company was HK$25.4 million, a decrease of HK$4.3 million compared to a loss of HK$29.7 million for the same period last year[9]. - Revenue for the six months ended June 30, 2024, was HK$22,007,000, a decrease of 5.4% compared to HK$23,259,000 in 2023[54]. - Gross profit increased to HK$6,782,000, up 38.1% from HK$4,906,000 in the previous year[54]. - Loss before income tax improved to HK$25,429,000, a reduction of 14.8% from HK$29,673,000 in 2023[54]. - Basic and diluted loss per share improved to HK(2.63) cents from HK(3.36) cents in the previous year[54]. - The consolidated loss before income tax for the six months ended June 30, 2024, was HK$25,429,000, compared to a loss of HK$29,673,000 for the same period in 2023, indicating an improvement of approximately 14.8%[77]. Revenue Breakdown - Revenue from the Medical Products Business was stable at HK$16.3 million, compared to HK$16.4 million in the same period last year, accounting for 74.2% of the Group's total revenue[9]. - Revenue from the Plastic Products Business decreased to HK$Nil million, down from HK$0.6 million in the same period last year, accounting for 0% of the Group's total revenue[12]. - Revenue from external customers for the Medical Devices Business was HK$16,327,000 for the six months ended 30 June 2024[67]. - The Money Lending Business generated revenue of HK$5,680,000 during the same period[67]. - Total reportable segment revenue for the Group was HK$22,007,000 for the six months ended 30 June 2024[67]. Expenses and Costs - Other losses during the period amounted to HK$22.9 million, compared to a loss of HK$20.3 million in the corresponding period of 2023[7]. - Distribution costs decreased by HK$0.5 million to HK$2.2 million during the period under review[9]. - Administrative expenses decreased by HK$4.2 million to HK$5.9 million, representing a decrease of 41.6% over the corresponding period last year[9]. - Finance costs amounted to HK$1.2 million, down from HK$1.4 million in the same period last year[9]. - The cost of inventories recognized as expenses for the six months ended June 30, 2024, was HK$15,225,000, a decrease from HK$17,908,000 in 2023, indicating a reduction of approximately 15%[83]. Investment and Assets - The Group recorded a net unrealised and realised loss of HK$22.9 million from its securities investment, compared to a loss of HK$11.0 million for the same period last year[19]. - As of 30 June 2024, the outstanding principal and interest amount of loan receivables was HK$147.0 million, down from HK$153.5 million as of 31 December 2023[16]. - As of June 30, 2024, the Group's consolidated net asset was approximately HK$35.9 million, a decrease of approximately HK$25.5 million from HK$61.4 million as of December 31, 2023[30]. - The Group's total cash and bank balances amounted to approximately HK$4.6 million as of June 30, 2024, down HK$3.1 million from HK$7.7 million as of December 31, 2023[30]. - The Group's gearing ratio increased to 73.2% as of June 30, 2024, compared to 37.8% as of December 31, 2023[30]. Share Options and Capital - The Share Option Scheme was adopted on June 30, 2015, to incentivize eligible participants for their contributions to the Group[45]. - The maximum number of shares that may be issued upon the exercise of all share options under the Share Option Scheme is capped at 10% of the issued share capital of the Company at the time of approval[46]. - The exercise price of share options must be at least the highest of the closing price on the grant date, the average closing price for the five business days preceding the grant date, or the nominal value of a share[46]. - The Company has authorized a maximum of 48,377,589 share options under the Share Option Scheme as of June 30, 2022[48]. - The issued and fully paid share capital as of June 30, 2024, is 967,551,792 shares, totaling HK$48,378,000[106]. Corporate Governance - The Company has complied with all code provisions of the Corporate Governance Code for the six months ended June 30, 2024[53]. - The Audit Committee has reviewed the accounting principles and practices adopted by the Group and discussed financial reporting matters for the six months ended June 30, 2024[53]. - The Company has confirmed full compliance with the Model Code for securities transactions by Directors during the six months ended June 30, 2024[53]. Employee and Management - The Group has 30 employees as of June 30, 2024, with remuneration largely based on performance and industry practices[39]. - The remuneration of key management personnel for the six months ended June 30, 2024, was HK$408,000, a decrease from HK$426,000 in the same period of 2023[109].
隽泰控股(00630) - 2024 - 中期业绩